BinD-19 (Shenzhen BinDeBio)

基因工程CD19抗原受体修饰自体T细胞

Report date: 2024/11/12 20:00:08

Base Information

Drug NameBinD-19 (Shenzhen BinDeBio)
Drug Alias NameBinD19BinD-19
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapyCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesShenzhen Bindebio Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesShenzhen Bindebio Ltd
Active IndicationsN/A
Inactive IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-LymphomaPrecursor Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A